751114
Last Update Posted: 2012-09-10
Recruiting has ended
All Genders accepted | 35 Years-70 Years |
515 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients
The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period.
Secondary objective was to assess the effect of insulin glargine in comparison with sitagliptin on:
- HbA1c level
- Fasting Plasma Glucose (FPG)
- 7-point plasma glucose (PG) profiles
- Percentage of patients with HbA1c <7% and <6.5%
Safety objectives consisted of:
- Hypoglycemia occurrence
- Body weight
- Overall safety
Eligibility
Relevant conditions:
Diabetes Mellitus, Type 2
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov